These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37700264)

  • 1. Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report.
    Burlo F; Tumminelli C; Pastore S; Stocco G; Curci D; Lucafò M; Tommasini A; Taddio A
    Pediatr Rheumatol Online J; 2023 Sep; 21(1):99. PubMed ID: 37700264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial.
    Ramanan AV; Dick AD; Guly C; McKay A; Jones AP; Hardwick B; Lee RWJ; Smyth M; Jaki T; Beresford MW;
    Lancet Rheumatol; 2020 Mar; 2(3):e135-e141. PubMed ID: 32280950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial).
    Ramanan AV; Dick AD; Jones AP; Guly C; Hardwick B; Hickey H; Lee R; McKay A; Beresford MW;
    BMC Rheumatol; 2018; 2():4. PubMed ID: 30886955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab Employment in the Treatment of Resistant Juvenile Idiopathic Arthritis Associated Uveitis.
    Maleki A; Manhapra A; Asgari S; Chang PY; Foster CS; Anesi SD
    Ocul Immunol Inflamm; 2021 Jan; 29(1):14-20. PubMed ID: 33021415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients.
    Calvo-Río V; Santos-Gómez M; Calvo I; González-Fernández MI; López-Montesinos B; Mesquida M; Adán A; Hernández MV; Maíz O; Atanes A; Bravo B; Modesto C; Díaz-Cordovés G; Palmou-Fontana N; Loricera J; González-Vela MC; Demetrio-Pablo R; Hernández JL; González-Gay MA; Blanco R
    Arthritis Rheumatol; 2017 Mar; 69(3):668-675. PubMed ID: 27696756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.
    Tappeiner C; Mesquida M; Adán A; Anton J; Ramanan AV; Carreno E; Mackensen F; Kotaniemi K; de Boer JH; Bou R; de Vicuña CG; Heiligenhaus A
    J Rheumatol; 2016 Dec; 43(12):2183-2188. PubMed ID: 27633821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema.
    Mesquida M; Molins B; Llorenç V; Sainz de la Maza M; Adán A
    Ophthalmology; 2014 Dec; 121(12):2380-6. PubMed ID: 25204610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema: A Multicenter Study from the French Uveitis Network.
    Leclercq M; Andrillon A; Maalouf G; Sève P; Bielefeld P; Gueudry J; Sené T; Moulinet T; Rouvière B; Sène D; Desbois AC; Domont F; Touhami S; El Chamieh C; Cacoub P; Bodaghi B; Biard L; Saadoun D
    Ophthalmology; 2022 May; 129(5):520-529. PubMed ID: 34793830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab for refractory uveitis associated with juvenile idiopathic arthritis: A report of two cases.
    Dipasquale V; Atteritano M; Fresta J; Castagna I; Conti G
    J Clin Pharm Ther; 2019 Jun; 44(3):482-485. PubMed ID: 30815892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab in severe and refractory non-infectious uveitis.
    Papo M; Bielefeld P; Vallet H; Seve P; Wechsler B; Cacoub P; Le Hoang P; Papo T; Bodaghi B; Saadoun D
    Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S75-9. PubMed ID: 25268663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.
    Foeldvari I; Nielsen S; Kümmerle-Deschner J; Espada G; Horneff G; Bica B; Olivieri AN; Wierk A; Saurenmann RK
    J Rheumatol; 2007 May; 34(5):1146-50. PubMed ID: 17343318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
    Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
    Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-6 inhibition in the management of non-infectious uveitis and beyond.
    Karkhur S; Hasanreisoglu M; Vigil E; Halim MS; Hassan M; Plaza C; Nguyen NV; Afridi R; Tran AT; Do DV; Sepah YJ; Nguyen QD
    J Ophthalmic Inflamm Infect; 2019 Sep; 9(1):17. PubMed ID: 31523783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis.
    Zulian F; Balzarin M; Falcini F; Martini G; Alessio M; Cimaz R; Cimino L; Zannin ME
    Arthritis Care Res (Hoboken); 2010 Jun; 62(6):821-5. PubMed ID: 20191477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review.
    Iannone C; Marelli L; Costi S; Pellico MR; La Franca L; Caporali R; Miserocchi E
    Children (Basel); 2023 Feb; 10(3):. PubMed ID: 36979992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis.
    Leclercq M; Goupillou P; Gomez H; Muraine M; Benhamou Y; Girszyn N; Gueudry J
    J Ophthalmic Inflamm Infect; 2023 Jul; 13(1):32. PubMed ID: 37462850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab and Abatacept for the Treatment of Childhood Chronic Uveitis: A Monocentric Comparison Experience.
    Maccora I; Abu Rumeileh S; Curci F; de Libero C; Marrani E; Mastrolia MV; Pagnini I; Simonini G
    Front Pediatr; 2022; 10():851453. PubMed ID: 35498797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab.
    Lanz S; Seidel G; Skrabl-Baumgartner A
    Pediatr Rheumatol Online J; 2021 Aug; 19(1):132. PubMed ID: 34419092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous Tocilizumab May Be Less Effective than Intravenous Tocilizumab in the Treatment of Juvenile Idiopathic Arthritis-associated Uveitis.
    Quesada-Masachs E; Caballero CM
    J Rheumatol; 2017 Feb; 44(2):260-261. PubMed ID: 28148759
    [No Abstract]   [Full Text] [Related]  

  • 20. [Tocilizumab for refractory systemic juvenile idiopathic arthritis].
    Lai JM; Wu FQ; Zhou ZX; Kang M; Huang XL; Su GX; Li SN; Zhu J; Wang XN
    Zhonghua Er Ke Za Zhi; 2017 Nov; 55(11):830-834. PubMed ID: 29141313
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.